Injectable Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029

The Injectable Drug Delivery Devices Market size is estimated at USD 114.85 billion in 2024, and is expected to reach USD 162.15 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).

Key Highlights

• The development of vaccines against COVID-19 is expected to significantly impact the growth of injectable drug delivery systems as a large-scale global vaccination program is underway, which has increased the demand for needles and syringes in the market. According to the June 2021 update from the Ministry of Health and Family Welfare of India, the Health Ministry has placed an order with the Serum Institute of India for 250 million doses of Covishield and with Bharat Biotech for 190 million doses of Covaxin to achieve universalization of vaccination in the country, which is expected to impact the market positively.
• Further, many companies launched new injectable drug delivery devices, which increased bioavailability and rapid and targeted drug delivery, which is also expected to significantly impact the growth of the studied market. Therefore, the COVID-19 pandemic significantly affected the market growth and is expected to have a significant impact on the growth of the injectable drug delivery devices market over the analysis period.
• The injectable drug delivery devices market is expected to show rapid growth due to the growing burden of chronic diseases, benefits, and convenience, leading to increased demand for self-injectors and growth of the biologics market, leading to increased demand for injectors.
• The growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes. It has been observed that most deaths by chronic diseases can be attributed to cardiovascular diseases, obesity, and diabetes. This is expected to affect emerging countries the most, as population growth is found to be the most significant factor in developing areas. For instance, globally, lung cancer is anticipated to affect nearly 3.5 million by 2040, as per the Global Cancer Observatory data updated in March 2021.
• In addition, as per the data published by the American College of Chest Physicians in July 2021, lung cancer is one of the most frequently diagnosed cancers and accounts for 11.6% of the total cancer cases globally. Worldwide, lung cancer incidents are estimated to increase by 38%, to 2.89 million, by 2030. Due to the increasing burden of such chronic diseases, the demand for injectable drugs and therapies is growing, and it is expected to create new opportunities for injectable drug delivery devices and contribute to the market's growth over the forecast period.
• Furthermore, the launch of new technologically integrated products developed by key players that are focused on improving dosage administration will drive market growth. For instance, in January 2022, SHL Medical's official partner, Innovation Zed, for connected pen injector solutions, planned to launch InsulCheck DOSE, a connected add-on device that transforms traditional pen injectors into smart solutions to support the monitoring of disease management regimens. Such engagement of market players for the development of technologically advanced products will boost the market during the forecast period.
• Therefore, technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical industry are the factors contributing to the market's growth. However, injuries and infections caused by needles and the increasing use of alternative drug delivery systems are expected to hinder the market's growth.

Injectable Drug Delivery Devices Market Trends

Prefilled Syringes Subsegment is Anticipated to Grow Significantly Over the Forecast Period

• The prefilled syringes segment is expected to hold a major share of the injectable drug delivery market due to the benefits associated with it and the high adoption of these syringes for the delivery of drugs. In addition, prefilled syringes provide greater patient safety by reducing the potential for inadvertent needle sticks and exposure to toxic products that can occur while drawing medication from vials. Therefore, these syringes are regarded as a safe and standard recommended delivery device for most modern vaccines, due to which the prefilled syringe segment is expected to grow significantly during the forecast period of the study.
• The growing demand for injectable drug delivery devices is leading to the launch of new devices, and as per business expansion initiatives, companies are making collaborations, partnerships, mergers, and acquisitions, which are further expected to increase the competition in the market and drive the studied market towards growth. For instance, in October 2021, NovaGuardSA Pro Safety System, a single-use accessory for prefilled ISO standard 0.5mL staked needle syringes, was launched in the Indian market by West Pharmaceutical Services, a global leader in innovative solutions for injectable medication and healthcare products.
• Additionally, in February 2022, Owen Mumford Pharmaceutical Services reported that its UniSafe 1mL safety device for prefilled syringes had been approved as a combination product in Asia. In Europe, regulatory approval has been granted for the product, and the product is now available on the market as a combination product with a drug for the treatment of rheumatoid arthritis.
• Thus, due to the continuous product developments and benefits of prefilled syringes, the studied segment is expected to witness growth during the analysis period.

The North America Region Dominates the Injectable Drug Delivery Devices Market

• North America holds a major share of the injectable drug delivery devices market and is expected to continue its growth trend in the future due to the increasing aging population and the rising number of chronic diseases that may influence the usage of injectable drug delivery devices.
• The injectable drug delivery devices market is expected to grow in the United States among other countries such as Canada and Mexico owing to the high prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and others, the presence of established and developed healthcare infrastructure, and the launch of new injectable devices in the market during the forecast period of the study.
• According to the American Cancer Society's 2023 report, over 1.9 million new cancers are expected to be recorded in the United States in 2023. Also, as per the same source, the risk of having cancer rises dramatically as one gets older, and in the United States, 80% of cancer patients are 55 or older, with 57% being 65 or older. Thus, the burden of cancer and associated risk among the geriatric population in the country is expected to create demand for various therapies available and create opportunities for injectable drug delivery devices. This is further expected to have a significant positive impact on the growth of the studied market.
• Further, according to the International Diabetes Federation's report of December 2021, about 32.2 million people were living with diabetes in the United States in 2021, and this number is estimated to increase to 36.3 million by 2045, and this increase in the diabetes patient pool is expected to drive demand for auto-injector pens such as BD Vystra disposable pen, EPIPEN JR and prefilled syringes for insulin injections, which is anticipated to boost the growth of the market studied in North America.
• With the growing demand for effective therapeutics for chronic diseases, company activities such as product launches, mergers and acquisitions, partnerships, and strategic collaborations are expected to augment growth in the studied market in the country. For instance, in February 2022, the United States Food and Drug Administration (FDA) approved Takeda's TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
• Additionally, in May 2022, Jabil Healthcare launched the Qfinity autoinjector platform, a simple, reusable, and modular solution for subcutaneous (SC) drug self-administration at a lower cost than the market alternatives supporting the emerging prioritization of sustainable drug delivery within the pharmaceutical industry in the United States.
• Therefore, due to the rising burden of chronic diseases and continuous product developments, the injectable drug delivery devices market is expected to grow in North America during the forecast period.

Injectable Drug Delivery Devices Industry Overview

The studied market is highly competitive. The companies present in the market are focused on product innovations, expansions, finding new markets, or innovating their core competency to expand their market shares. There are also innovations taking place in injectable drug delivery systems that are the trend in the global injectable drug delivery market. Major players in the market studied are Baxter International Inc., Becton Dickinson and Company, Gerresheimer AG, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support